The Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves' Ophthalmopathy Patients | oneGRAVESvoice
Global Search
Global Search

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Back to Evidence & Education / Scientific Articles

The Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves’ Ophthalmopathy Patients

key information

source: Pharmacology

year: 2017

authors: Li J, Xiao Z, Hu X, Li Y, Zhang X, Zhang S, Gong W, Zhao J, Ye X

summary/abstract:

Purpose:
The purpose of this study is to examine the effectiveness of introducing both rituximab (RTX) and 131I for active Graves’ ophthalmopathy (GO) with hyperthyroidism.

Methods:
In total, 217 patients suffering from active GO with hyperthyroidism were included in this research. All subjects were randomly assigned to 3 groups. Patients in group A solely received 131I treatment; group B1 underwent a methylprednisolone treatment in combination with 131I treatment; and group B2 received an RTX in combination with 131I treatment. Hyperthyroidism treatment outcomes, orbital volumetry, ophthalmic assessments, serum cytokine levels, and adverse effects were measured after treatment.

Results:
The orbital volumetry principle was significantly different from 24 weeks after the start of treatment among all 3 groups, and improvements in most ophthalmic parameters were regarded significantly different among 3 groups (all p < 0.05). The expression levels of miR-146a and most serum cytokines were regarded significantly different from 24 weeks after the start of treatment among 3 groups (all p < 0.05).

Conclusions:
In comparison with other therapies, RTX treatment in combination with 131I treatment is considered to be more effective for hyperthyroidism with active GO.

organization: Yinzhou Hospital of Ningbo University Medical College, China

DOI: 10.1159/000453618

read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Powered by

Brought to you by

Supported through an independent
educational grant by

© 2022 rareLife solutions Inc.